According to a «Dell
Special Committee Investor Presentation» compiled, in part, by the Boston Consulting Group and filed with the SEC on July 15, it's clear that Dell has a spending problem.
Not exact matches
Activist hedge fund
investor and recent Valeant Pharmaceuticals (vrx) board appointee Bill Ackman on Wednesday slammed the company's steep drug price hikes in testimony before the U.S. Senate
Special Committee on Aging, going so far as to say the cost bumps «contributed to healthcare inflation and called into question the company's commitment to the patients it serves.»
Institutional
investors believe the
special committee should have advised shareholders that the price of freedom was too high.
The
special committee, which was formed to independently assess what the best option for Dell shareholders is, came to that conclusion based on its meetings with
investors as well as concerns over a key upcoming recommendation by investment advisory firm ISS, the person said.
The company's outgoing CEO Michael Pearson will be testifying before the Senate
Special Committee on Aging late Wednesday afternoon, along with activist
investor William Ackman, a majority shareholder and board member, and Howard Schiller, a director and former chief financial officer.
The Edward Jones Investment Policy
Committee offers its viewpoints on the U.S. economy, equities, the bond market, international markets and asset classes, as well as a
special topic of interest to
investors each quarter.